HT-6184

· Halia Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for HT-6184, covering 2025-03-30 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia [Phase 2]